Nivolumab plus Ipilimumab in Advanced Melanoma | Zendy

Jedd D. Wolchok | Zendy; Harriet M. Kluger | Zendy; Margaret K. Callahan | Zendy; Michael A. Postow | Zendy; Naiyer A. Rizvi | Zendy; Alexander M. Lesokhin | Zendy; Neil H. Segal | Zendy; Charlotte E. Ariyan | Zendy; RuthAnn Gordon | Zendy; Kathleen Reed | Zendy; Matthew M. Burke | Zendy; Anne Caldwell | Zendy; Stephanie Anne Kronenberg | Zendy; Blessing Agunwamba | Zendy; Xiaoling Zhang | Zendy; Israel Lowy | Zendy; H. David Inzunza | Zendy; William F. Feely | Zendy; Christine E. Horak | Zendy; Quan Hong | Zendy; Alan J. Korman | Zendy; Jon M. Wigginton | Zendy; Ashok Gupta | Zendy; Mario Sznol | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Nivolumab plus Ipilimumab in Advanced Melanoma

Author(s) -

Jedd D. Wolchok,

Harriet M. Kluger,

Margaret K. Callahan,

Michael A. Postow,

Naiyer A. Rizvi,

Alexander M. Lesokhin,

Neil H. Segal,

Charlotte E. Ariyan,

RuthAnn Gordon,

Kathleen Reed,

Matthew M. Burke,

Anne Caldwell,

Stephanie Anne Kronenberg,

Blessing Agunwamba,

Xiaoling Zhang,

Israel Lowy,

H. David Inzunza,

William F. Feely,

Christine E. Horak,

Quan Hong,

Alan J. Korman,

Jon M. Wigginton,

Ashok Gupta,

Mario Sznol

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1302369

Subject(s) - ipilimumab , medicine , nivolumab , regimen , adverse effect , melanoma , oncology , cancer , immunotherapy , cancer research

In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis of their distinct immunologic mechanisms of action and supportive preclinical data, we conducted a phase 1 trial of nivolumab combined with ipilimumab in patients with advanced melanoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research